Media ReleasesElixinol Global

View All Elixinol Global News

Elixinol Global enters into exclusive License Agreement in Japan

Elixinol Global Limited (Elixinol Global or the Company) (ASX:EXL; OTC:ELLXF) is pleased to announce that it has signed an exclusive Trademark and Know-How License Agreement (Agreement) with Elixinol Co., Ltd (Elixinol Japan), ensuring Elixinol can continue to build on its market leadership position in Japan, one of Asia’s biggest cannabidiol (CBD) markets.

Under the terms of the agreement, Elixinol Japan can use Elixinol trademarks and know-how in connection with the manufacture, advertising, distribution and sale of licensed CBD products in Japan. The Agreement is for two years with an automatic renewal of a further three year term and requires Elixinol Japan to pay Elixinol Global royalties equal to 3% of Elixinol Japan’s net sales for the first year, then a royalty of 5% on net sales for subsequent years. In line with EXL’s growth strategy, a portion of the royalties will be reinvested in growing the Elixinol brand further in Japan. Elixinol products will be manufactured in Japan to meet market specific regulatory requirements. 

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.